Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
alkaloid
Hallucinogen |
| gptkbp:biosynthesized_from |
tryptophan
|
| gptkbp:boilingPoint |
160–180 °C (decomposes)
|
| gptkbp:CASNumber |
61-50-7
|
| gptkbp:category |
alkaloid
Hallucinogen recreational drug serotonergic psychedelic entheogen |
| gptkbp:chemicalFormula |
C12H16N2
|
| gptkbp:color |
white to yellow crystalline solid
|
| gptkbp:component |
gptkb:ayahuasca
|
| gptkbp:discoveredBy |
gptkb:Richard_Helmuth_Fredrick_Manske
|
| gptkbp:discoveredIn |
1931
|
| gptkbp:duration_of_effects |
2-6 hours (oral with MAOI)
5-30 minutes (smoked) |
| gptkbp:effect |
mystical experiences
hallucinations altered perception of time |
| gptkbp:featuredIn |
book 'DMT: The Spirit Molecule'
|
| gptkbp:foundIn |
some animals
various plants |
| gptkbp:hasStreet |
gptkb:Dimitri
the spirit molecule |
| https://www.w3.org/2000/01/rdf-schema#label |
dimethyltryptamine (DMT)
|
| gptkbp:IUPACName |
2-(1H-indol-3-yl)-N,N-dimethylethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK) illegal in many countries |
| gptkbp:meltingPoint |
44–46 °C
|
| gptkbp:metabolism |
gptkb:monoamine_oxidase
|
| gptkbp:molecularWeight |
188.27 g/mol
|
| gptkbp:notableContributor |
gptkb:Rick_Strassman
|
| gptkbp:potential_medical_use |
studied for PTSD
studied for anxiety studied for depression |
| gptkbp:receptor_affinity |
5-HT2A receptor agonist
|
| gptkbp:routeOfAdministration |
smoked
oral (with MAOI) vaporized |
| gptkbp:solubility |
slightly soluble in water
soluble in ethanol |
| gptkbp:studiedBy |
psychedelic studies
|
| gptkbp:used_in |
traditional South American shamanic practices
|
| gptkbp:bfsParent |
gptkb:Psychotria
|
| gptkbp:bfsLayer |
7
|